

Declaration of Conformity

as per Annex IV of the Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 via BSI as the Notified Body (registration no. BSI-NL 2797)

Document No.: DOC-2022-14

Manufacturer: Roche Molecular Systems, Inc.

1080 US Highway 202 South Branchburg, NJ 08876

USA

Authorized Roche Diagnostics GmbH Representative: Sandhofer Strasse 116

68305 Mannheim

Germany

Name, Address and Identification BSI Group The Netherlands B.V. Notified Body Number: 2797

number of the Say Building, John M. Keynesplein 9, 1066 EP

Notified Body: Amsterdam, Netherlands

Roche Molecular Systems, Inc. declares that the *in vitro* diagnostic medical device:

Product Name: cobas® HBV/HCV/HIV-1 Control Kit

Positive control kit for use on the cobas® 5800/6800/8800 Systems

P/N: 09040773190

Complies with the requirements of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices.

This declaration is supported by the following certificates:

EC Certificate – Full Quality Assurance: CE 707974, first issued 2019-03-26, valid until 2026-05-26 EC Design-Examination Certificate: CE 709228, first issued 2019-03-26, valid until 2025-05-26

The Manufacturer agrees to develop, implement, and maintain a documented post-production monitoring process, including the notification of reportable events, under the European Medical Device Vigilance System Guidelines. As a legal manufacturer, Roche Molecular Systems, Inc., is solely responsible for the product. This declaration is issued under the sole responsibility of Roche Molecular Systems, Inc.

SOP 030.04.60TMPB – Version: 11 Page 1



Declaration of Conformity as per Annex IV of the Directive 98/79/EC of the European Parliament

as per Annex IV of the Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 via BSI as the Notified Body (registration no. BSI-NL 2797)

Document No.: DOC-2022-14	
Place: Tucson, AZ	Place: Pleasanton, CA
Date: 19-May-2022	Date: 17-May-2022
Jeff Boone	Rita Hoady
Jeff Boone Vice President, Quality Management	Rita Hoady Network Lead Molecular Lab Director, Global Regulatory Affairs

SOP 030.04.60TMPB - Version: 11 Page 2